{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:34:55Z","timestamp":1790480095366,"version":"4.1.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,24]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>We aimed to characterize the clinical phenotype of patients with SSc based on autoantibodies (topoisomerase antibody (Scl-70), ACA and ANA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We included patients with SSc who fulfilled the 2013 ACR\/EULAR criteria, with disease duration \u226415\u2009years. Six groups of patients were defined: ACA-lcSSC, Scl-70-lcSSc, ANA-lcSSc, Scl-70-dcSSc, ANA-dcSSc and ACA-dcSSc patients. We compared the different groups of patients. In the ANA subgroup, we included patients negative for SSc-specific antibodies (Scl-70 and ACA). We assessed the following: risk of interstitial lung disease (ILD), myositis, scleroderma renal crisis, cardiac involvement, gastrointestinal involvement, pulmonary hypertension, treatment, cancer and all-cause mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred and thirteen SSc patients were included: 72 (64%) females, 82 (73%) lcSSc and 31 (27%) dcSSc. Among patients with lcSSc, 43 (52%) were ACA+, 16 (19%) Scl-70+ and 23 (28%) ANA+, and among patients with dcSSc, 13 (42%) patients were Scl-70+, 11 (35%) ANA+ and 7 (23%) ACA+. Scl-70-lcSSc patients had a significantly shorter time from RP to SSc diagnosis (P\u2009=\u20090.04), higher CRP (P\u2009=\u20090.04), renal scleroderma crisis (P\u2009=\u20090.02), ILD (P\u2009=\u20090.03) and diastolic dysfunction (P\u2009=\u20090.04) than ANA-lcSSc patients. Scl-70-dcSSc patients had a higher rate of myositis (P\u2009=\u20090.04), renal crisis (P\u2009=\u20090.03), CRP elevation (P\u2009=\u20090.002), ILD (P\u2009=\u20090.04), pericardial effusion (P\u2009=\u20090.03) and cancer (P\u2009=\u20090.04) than ANA-dcSSc patients. The risk of ILD was higher in Scl-70 patients during the first 10\u2009years than in ACA+ and ANA+ patients (P\u2009=\u20090.03 and P\u2009=\u20090.02, respectively). The risk of major organ involvement was higher in Scl-70+ patients, followed by ANA+ and ACA+ patients, throughout 15\u2009years of follow-up. All-cause mortality was higher in dcSSc patients than in lcSSc patients, but no differences were found regarding antibody positivity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We have characterized the clinical phenotype of patients based on autoantibodies: Scl-70 patients show the greatest risk of major organ involvement, followed by ANA+ patients and ACA+ patients. The risk of ILD in Scl-70+ patients suggests that these patients should be monitored closely, irrespective of skin involvement. These results might provide new ways to help with the early diagnosis and management and in assessment of the prognosis of the disease.<\/jats:p><\/jats:sec>","DOI":"10.1093\/rap\/rkad010","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T07:07:17Z","timestamp":1679641637000},"page":"i26-i33","source":"Crossref","is-referenced-by-count":13,"title":["Clinical phenotype in scleroderma patients based on autoantibodies"],"prefix":"10.1093","volume":"7","author":[{"given":"Cristiana Sieiro","family":"Santos","sequence":"first","affiliation":[{"name":"Rheumatology Department, Complejo Asistencial Universitario de Le\u00f3n , Le\u00f3n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara Moriano","family":"Morales","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Complejo Asistencial Universitario de Le\u00f3n , Le\u00f3n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina \u00c1lvarez","family":"Castro","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Complejo Asistencial Universitario de Le\u00f3n , Le\u00f3n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira D\u00edez","family":"\u00c1lvarez","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Complejo Asistencial Universitario de Le\u00f3n , Le\u00f3n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,24]]},"reference":[{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"65","author":"Van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/2397198319870667","article-title":"Pathogenic roles of autoantibodies in systemic sclerosis: current understandings in pathogenesis","volume":"5","author":"Sen\u00e9cal","year":"2020","journal-title":"J Scleroderma Related Disord"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrrheum.2009.238","article-title":"Autoantibodies as predictive tools in systemic sclerosis","volume":"6","author":"Nihtyanova","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"2023032821414020800_","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/rheumatology\/keg170","article-title":"The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis","volume":"42","author":"Scheja","year":"2003","journal-title":"Rheumatology"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/rheumatology\/kez005","article-title":"Prognostic properties of antitopoisomerase antibodies in patients identified by the ACR\/EULAR 2013 systemic sclerosis criteria","volume":"58","author":"Boonstra","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"102583","DOI":"10.1016\/j.autrev.2020.102583","article-title":"Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets","volume":"19","author":"Mahler","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/art.1780310207","article-title":"Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis","volume":"31","author":"Steen","year":"1988","journal-title":"Arthritis Rheum"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.22747","article-title":"Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody","volume":"56","author":"Perera","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/art.41403","article-title":"Association of anti-topoisomerase I antibodies of the IgM isotype with disease progression in anti-topoisomerase I-positive systemic sclerosis","volume":"72","author":"Boonstra","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"R172","DOI":"10.1186\/ar3495","article-title":"Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features","volume":"13","author":"Mierau","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/2397198319869564","article-title":"Prediction of organ involvement and survival in systemic sclerosis patients in the first 5\u2009years from diagnosis","volume":"5","author":"Van den Hombergh","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1136\/annrheumdis-2019-215787","article-title":"Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual","volume":"78","author":"Fasano","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/art.40906","article-title":"Phenotypes determined by cluster analysis and their survival in the prospective European scleroderma trials and research cohort of patients with systemic sclerosis","volume":"71","author":"Sobanski","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rdc.2007.12.001","article-title":"The many faces of scleroderma","volume":"34","author":"Steen","year":"2008","journal-title":"Rheum Dis Clin North Am"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1183\/09031936.05.00035205","article-title":"Interpretative strategies for lung function tests","volume":"26","author":"Pellegrino","year":"2005","journal-title":"Eur Respir J"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/ard.2009.127621","article-title":"Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma","volume":"70","author":"Domsic","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1164\/rccm.201903-0486OC","article-title":"Tracking impact of interstitial lung disease in systemic sclerosis in a complete nationwide cohort","volume":"200","author":"Hoffmann-Vold","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/rheumatology\/key151","article-title":"Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease","volume":"58","author":"Tashkin","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1093\/rheumatology\/keac188","article-title":"EUSTAR collaborators. Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from EUSTAR cohort","volume":"61","author":"Zanatta","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"28","author":"Lang","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2023032821414020800_","first-page":"1179","article-title":"Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer","volume":"77","author":"Igusa","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.semarthrit.2015.04.009","article-title":"Thinking outside the box\u2014The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect","volume":"45","author":"Srivastava","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/rheumatology\/kew298","article-title":"Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study","volume":"55","author":"Kranenburg","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13075-021-02548-1","article-title":"Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort","volume":"23","author":"Jaafar","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972\u20132002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2023032821414020800_","first-page":"458","article-title":"Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization","volume":"35","author":"Hsu","year":"2008","journal-title":"J Rheumatol"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/apt.13963","article-title":"Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis","volume":"45","author":"Kumar","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2023032821414020800_","first-page":"S378","article-title":"Gastric antral vascular ectasia (GAVE) in early diffuse SSc: report from the SCOT trial","volume":"58","author":"Mayer","year":"2008","journal-title":"Arthritis Rheumatol"},{"key":"2023032821414020800_","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/23971983211053246","article-title":"Primary systemic sclerosis heart involvement: a systematic literature review and preliminary data-driven, consensus-based WSF\/HFA definition","volume":"7","author":"Bruni","year":"2022","journal-title":"J Scleroderma Relat Disord"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/7\/Supplement_1\/i26\/49680346\/rkad010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/7\/Supplement_1\/i26\/49680346\/rkad010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T14:30:13Z","timestamp":1702132213000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/7\/Supplement_1\/i26\/7077173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":34,"journal-issue":{"issue":"Supplement_1","published-print":{"date-parts":[[2023,3,24]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkad010","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4,1]]},"published":{"date-parts":[[2023,3,24]]}}}